General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview


  • Prevotella scopos is a Gram-negative, non-spore-forming, strictly anaerobic, non-motile, rod-shaped bacterium. It has been detected in at least 2 gut microbiome compilation studies or metastudies. The DNA G+C content is 41%. Prevotella scopos is likely to be transient and not a long-term gut coloniser. (Downes2011a)



  • This organism has been recovered from the oral cavity. Pathogenicity status unknown, or very unlikely to be pathogenic. Likely to be transient and not a long-term gut commensal.

  • GENERAL CHARACTERISTICS (Downes2011a);
    Character Response
  • Substrates hydrolysed or digested:
  • gelatin;
  • pH
  • Acidity tolerance:
  • tolerates pH 6.0; Grows optimally at pH 7.
  • 🌡
  • Temperature tolerance:
  • grows at 30℃; grows at 42℃; Grows optimally at 35℃.
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; glucose; mannose; lactose; maltose; melezitose; raffinose; sucrose;
  • Active enzymes:
  • Ala arylamidase; alkaline phosphatase; Arg arylamidase; N-Ac β-glucosaminidase; fucosidase; α-galactosidase; β-galactosidase; α-glucosidase; Glu-Glu arylamidase; Leu-Gly arylamidase;

  • SPECIAL FEATURES (Downes2011a);
    Character Response
  • Metabolites produced:
  • acetate; lactate (trace); isobutyrate (minor); succinate (major); isovalerate;
  • Metabolites not produced:
  • indole;
  • Nitrate:
  • not reduced
  • Pigments:
  • light orange

  • RESPONSE TO ANTIBIOTICS (Downes2011a);
    Class Active Resistant
  • Aminoglycosides:
  • kanamycin;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • colistin;

  • Details


    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Bacteroidetes Class:  Bacteroidia Order:  Bacteroidales Family:  Prevotellaceae Genus:  Prevotella Gram stain:  neg O2 Relation.:  strictly anaerobic Spore:  No spore Motility:  Sessile Morphology:  Rod Pigment:  light orange
    Health:  Unknown
    Source:  the oral cavity
    DNA G+C(%):  41
    Opt. T:  35℃
    Lower T(℃):  30(+)
    High T(℃):  42(+)
    Opt. pH:  7
    pH 6.0-8.0:  6.0(+)
    Aesculin:  neg Urea:  neg Gelatin:  + Arginine:  neg

    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Arabinose:  neg Fructose:  + Glucose:  + Mannose:  + Rhamnose:  neg Ribose:  neg Xylose:  neg Cellubiose:  neg Lactose:  + Maltose:  + Melezitose:  + Sucrose:  + Trehalose:  neg Mannitol:  neg Sorbitol:  neg Salicin:  neg

    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  neg Ac-β-glcamnd:  + α-Fucosidase:  + α-Galactosidase:  + β-Galactosidase:  + α-Glucosidase:  + β-Glucosidase:  neg β-Glucuronidase:  neg α-Mannosidase:  neg Chymotrypsin:  neg Trypsin:  neg AlanineAA:  + ArgAA:  + CystineAA:  neg GluGluAA:  + HisAA:  w LeuAA:  w LeuGlyAA:  + ValAA:  neg AlkalineP:  + AcidP:  neg Esterase(C4):  neg EstLip(C8):  neg Lipase(C14):  neg

    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    Acetate:  + Lactate:  trace(+) Isobutyrate:  minor(+) Succinate:  Major(+) Isovalerate:  + Indole:  neg Pigment:  light orange

    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    kanamycin:  Res
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    vancomycin:  Res
    colistin:  Res

    References


    SPECIFIC REFERENCES FOR PREVOTELLA SCOPOS
  • Downes2011a - Prevotella fusca sp. nov. and Prevotella scopos sp. nov., isolated from the human oral cavity.
  • ...............................
  • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR PREVOTELLA SCOPOS
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • New2022 - Collective effects of human genomic variation on microbiome function.
  • ...............................